Posts Tagged ‘cancer treatment’
Monday, November 1st, 2010
ATLANTA - Celtaxsys Inc., a company with a technology that modulates inflammatory response, has raised $4.2 million, according to a regulatory filing.
According to the filing with the US Securities and Exchange Commission, the company raised the new funds from six investors.
Located in the Georgia Tech Advanced Technology Development Center, Celtaxis is working on a unique way to get immune system cells to where they’re needed and block them when they’re not.
The company says it is initially focused on treatments for cancer.
The technology could lead to new drugs to treat autoimmune diseases such as lupus, rheumatoid arthritis and others as well.
Founded in 2004, Celtaxsys raised $2.04 million of a debt offering in 2009 and $5.7 million from Master’s Capital and GLG, the largest hedge fund in Europe, in 2005.
In a previous interview with TechJournal South, Celtaxsys CEO William Riddick, president, said the company’s “secret sauce” is a series of assays that detect and quantify chemo-repulsion. “By using these, we’re able to detect and identify proteins that signal the immune system to move backwards,” he said.
That is important for several reasons. “A whole series of diseases are caused by too many immune cells aggregating in the wrong place,” he said.
“In asthma, for instance, errant signals tell immune cells to go to the lungs, which causes difficulty in breathing.” Remove them and you can treat the asthma.”
Initially, the company is focused on cancerous tumors that make chemo-repellants to chase away immune system cells. When they do that, the tumors grow.
“Our compounds would block the chemo-repellant to get a more complete immune response with fewer side effects,” he said.
“All we really do is allow the immune system to do what it’s already primed to do.”
He says the company believes it will be able to identify effective chemo-repellants that can be used as drugs.
It would prefer to find chemical agents as opposed to proteins, which are expensive to make and sell.
Celtaxsys seeks partnerships with companies that have large compound libraries.
For our 2008 profile of the company, see: Celtaxis system modifies inflammatory response
Tags: Atlanta, cancer treatment, Celtaxis, financing, inflammatory response Posted in Biotech, Georgia, Money, Pharma | Comments Off
Tuesday, October 26th, 2010
ATLANTA—Researchers at Emory University and the Georgia Institute of Technology will join forces against head and neck cancers and pancreatic cancer using two grants from the National Cancer Institute’s Cancer Nanotechnology Platform Partnerships (CNPP) program. The cooperative five-year grants totaling $4.7 million will be used to develop nanoparticles as diagnostic and therapeutic tools against cancers.
The first grant totals more than $2.3 million over five years and is awarded to Dong Moon Shin, MD, professor of hematology, medical oncology and otolaryngology and director of the Winship Cancer Chemoprevention program, and Mostafa El-Sayed, PhD, Regents professor of chemistry and biochemistry and director of the Laser Dynamics Laboratory at Georgia Institute of Technology.
Their project, titled “Toxicity and efficacy of gold nanoparticle photothermal therapy in cancer,” is aimed at head and neck cancer, which develops in the soft tissues of the mouth and throat.
“We are excited and grateful for the opportunity to combine our laboratories’ biological and chemical expertise and to develop gold nanoparticle phototherapy into an effective tool against head and neck cancer,” says Shin.
When a laser is tuned to certain wavelengths, gold nanoparticles will absorb the energy and convert it to heat, thanks to a phenomenon known as “surface plasmon resonance.” Directing the nanoparticles to “home in” on cancer cells enables the laser to selectively kill them.
Researchers plan to target the molecule EGFR (epidermal growth factor receptor), which is found on almost all head and neck cancers, by binding the gold nanoparticles to antibodies against EGFR. Studies in animals on the toxicity of gold nanoparticles and how fast they move within the body are necessary before application in humans.
The second NCI grant for nearly $2.4 million over five years will be used to develop magnetic iron oxide nanoparticles as tools against pancreatic cancer, one of the most deadly of all cancer types. The principle investigators are Lily Yang, MD, PhD, associate professor of surgery and Hui Mao, PhD, associate professor of radiology and Center for Systems Imaging, both at Emory University School of Medicine.
The project, titled “Theranostic nanoparticles for targeted treatment of pancreatic cancer,” aims to combine the function of MRI visualization with drug delivery capabilities for pancreatic cancer therapy and diagnosis (thera – nostics).
Using magnetic iron oxide nanoparticles developed by Yang and Mao and their teams, researchers plan to improve the delivery of chemotherapeutic agents by directing drug-carrying nanoparticles to the molecule uPAR (urokinase plasminogen activator receptor), which is prevalent in pancreatic cancer cells.
Magnetic iron oxide nanoparticles will be loaded with different types of drug molecules that can be released at the site of the tumor or even inside of the tumor cells. “These nanoparticles can be tracked by magnetic resonance imaging (MRI),” says Yang, “so we will test our ability to monitor drug delivery and treatment responses with imaging technology.”
Other institutions receiving CNPP grants are Cedars-Sinai Medical Center; Children’s Hospital of Los Angeles; University of North Carolina; Northeastern University; Northwestern University; Rice University; University of Cincinnati; University of Nebraska Medical Center; University of New Mexico Health Sciences Center; and the University of Utah.
Tags: cancer treatment, Emory, GA Tech, Nanotech, Pharma, University research Posted in Biotech, Georgia, Money, Nanotech, University Tech | 1 Comment »
Wednesday, September 29th, 2010
BONITA SPRINGS, FL – Tigris Pharmaceuticals Inc., a drug development company, has completed a private placement of Series C Convertible Preferred Stock resulting in gross proceeds of approximately $6.5 million.
The financing, which was led by Neil Flanzraich, also included current investors Wexford Spectrum Investors, and Sonostar Capital Partners, and other institutional and individual investors.
Flanzraich has been named executive chair of the company’s board.
Tigris intends to use the proceeds from the financing primarily to advance the development of its clinical product pipeline, including its lead compound, Aminoflavone pro-drug (AFP-464), a novel anticancer agent. It has shown some effectiveness in inhibiting tumor cell growth, with breast, ovarian, lung and renal tumor cell lines exhibiting particular sensitivity to the compound.
The company is initiating a Phase II clinical trial of the product in patients with breast cancer.
It is is also conducting a multi-center Phase I dose escalation study for GGTI-2418, another first-in-class agent.
We hope the large number of new, first-in-class anti-cancer treatments in pipelines of Southeast firms continue to show muscle in the fight against the disease.
–Allan Maurer
To contact TJS editor Allan Maurer: Allan at TechJournalSouth dot com.
Tags: Bonita Springs, cancer treatment, financing, FL, private placement, Tigris Pharmaceuticals Posted in Biotech, Florida, Healthcare, Money, Pharma | Comments Off
Monday, August 30th, 2010
BALTIMORE, MD – Gliknik, a biopharmaceutical company developing treatments for cancer and autoimmune diseases, has raised $1.9 million of a targeted $4 million equity round that includes warrants and options, according to a regulatory filing.
The company disclosed in June that Maryland Health Care Product Development Corp. (MHCPDC) had invested an undisclosed amount in the company and said it would invest an additional amount of equity this summer.
The MHCPDC is a non-profit venture investment organization and a supporting organization of the Tech Council of Maryland.
The company also raised a $3.6 million round in Janurary.
The company evolved from research by Dr. Scott Strome professor of Otorhinolarynogology-Head & Neck Surgery at the University of Maryland School of Medicine in Baltimore.
The company was founded by David S. Block, CEO and president, who was previously a senior executive at DuPont Merck and was COO of Celera Genomics. A serial entrepreneur, he also previously founded Ruxton Pharmaceuticals in 2004, a venture-backed startup.
Gliknik disclosed the funding in a filing with the US Securities and Exchange Commission.
To contact TechJournal South Editor & Writer Allan Maurer: Allan at TechJournalSouth dot com.
Tags: Atlanta, autoimmune diseases, Baltimore, Biotech, cancer treatment, financing, GA, Gliknik, immune system modulation, MD Posted in Biotech, Georgia, Maryland, Money, Pharma, Potomac | Comments Off
Wednesday, July 28th, 2010
CHAPEL HILL – A normally benign protein found in the human body appears to be able – when paired with nanoparticles – to zero in on and kill certain cancer cells, without having to also load those particles with chemotherapy drugs.
The finding could lead to a new strategy for targeted cancer therapies, according to the University of North Carolina at Chapel Hill scientists who made the discovery.
However, they also cautioned that the result raises concerns about unanticipated “off-target” effects when designing nano-delivery agents.
Transferrin, the fourth most abundant protein in human blood, has been used as a tumor-targeting agent for delivering cancer drugs for almost two decades. The protein’s receptor is over-expressed on the surface of many rapidly growing cancers cells, so treatments combined with transferrin ligands are able to seek out and bind to them. Nanoparticles infused with transferrin have long been regarded as safe and nontoxic.
Now, UNC researchers have shown that, surprisingly, attaching transferrin to a nanoparticle surface can effectively and selectively target and kill B-cell lymphoma cells, found in an aggressive form of non-Hodgkin’s lymphoma. It had been thought that nanoparticles would also need to carry toxic chemotherapy agents to have such an effect.
The scientists say the result is an interesting development in the field of nanomedicine, which researchers hope will eventually provide widely accepted alternatives – or replacements – to chemo and radiation treatment.
The discovery was made by a team of researchers led by Joseph DeSimone, Ph.D., Chancellor’s Eminent Professor of Chemistry in UNC’s College of Arts and Sciences and William R. Kenan Jr. Distinguished Professor of Chemical Engineering at North Carolina State University, along with Jin Wang, Ph.D., and Shaomin Tian, Ph.D., in DeSimone’s lab. Their findings appear in this week’s online issue of the Journal of the American Chemical Society.
Tags: cancer treatment, Joseph DeSimone, nanoparticles, Nanotech, UNC Chapel Hill Posted in Biotech, Carolinas, Healthcare, North Carolina, University Tech | Comments Off
|
|
|